BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//talks.cam.ac.uk//v3//EN
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
CATEGORIES:Darwin College Science Seminars
SUMMARY:Enhancing dimensionality of in-vitro GPCR drug dis
 covery - Ned Wills
DTSTART;TZID=Europe/London:20240118T131000
DTEND;TZID=Europe/London:20240118T140000
UID:TALK209425AThttp://talks.cam.ac.uk
URL:http://talks.cam.ac.uk/talk/index/209425
DESCRIPTION:As the largest super-family of membrane bound rece
 ptor proteins\, G Protein-Coupled Receptors (GPCRs
 ) play crucial roles not only in everyday physiolo
 gy\, but many pathologies. Although over a third o
 f FDA approved pharmaceuticals target GPCRs\, many
  prospective drug candidates fail due to on-target
  but undesirable effects. Such adverse effects are
  likely due to the pleiotropic nature of GPCR sign
 alling pathways. Here\, the development of a novel
  biosensor platform for investigating this pleiotr
 opy is outlined and the first iteration presented.
  The Multi-Response Element GPCR Sensor (MREGS) al
 lows for the simultaneous investigation of five si
 gnalling events downstream of GPCR activation usin
 g a multiplexed based assay system (Sarrion-Perdig
 ones et al.\, 2019). This system can now be applie
 d to search for more pathway specific pharmaceutic
 als with fewer side effects. 
LOCATION:Richard King room\, Darwin College
CONTACT:
END:VEVENT
END:VCALENDAR